COMPANY DESCRIPTION: StageZero Life Sciences Ltd. (“StageZero” or “the Company”) develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. The Company’s first product was ColonSentry®, a blood test to determine an individual’s current risk for having colorectal cancer. In April, StageZero commercially launched Aristotle®, the first-ever multi-cancer panel that simultaneously screens for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. At the same time, StageZero announced the acquisition of Health Clinics and Care Oncology to launch an early cancer diagnostic program under the trade name AVRT that is based on Aristotle®. In the midst of last year’s pandemic, StageZero expanded its offerings by launching a new COVID-19 testing service, offering both the serology and lab-based polymerase chain reaction (PCR) tests, and a saliva-based PCR test. StageZero’s full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups. STOCK PRICE VALUATION SUMMARY: Using a 1-Year Forward Revenue Estimate of US$23.0 million as a baseline, and (1) Revenue Multiples: We estimate that StageZero’s stock price should be in the range of $1.24 to $3.99; (2) Prior Mergers & Acquisitions (M&A): We estimate that StageZero’s stock price should be in the range of $0.67 to $14.14; (3) The Discounted Cash Flow (DCF) Method: We estimate that StageZero’s stock price should be $3.18 in one year.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
StageZero Valuation Report Shows Upside Potential
- Published:
27 Jun 2021 -
Author:
Chris Thompson -
Pages:
27
COMPANY DESCRIPTION: StageZero Life Sciences Ltd. (“StageZero” or “the Company”) develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. The Company’s first product was ColonSentry®, a blood test to determine an individual’s current risk for having colorectal cancer. In April, StageZero commercially launched Aristotle®, the first-ever multi-cancer panel that simultaneously screens for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. At the same time, StageZero announced the acquisition of Health Clinics and Care Oncology to launch an early cancer diagnostic program under the trade name AVRT that is based on Aristotle®. In the midst of last year’s pandemic, StageZero expanded its offerings by launching a new COVID-19 testing service, offering both the serology and lab-based polymerase chain reaction (PCR) tests, and a saliva-based PCR test. StageZero’s full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups. STOCK PRICE VALUATION SUMMARY: Using a 1-Year Forward Revenue Estimate of US$23.0 million as a baseline, and (1) Revenue Multiples: We estimate that StageZero’s stock price should be in the range of $1.24 to $3.99; (2) Prior Mergers & Acquisitions (M&A): We estimate that StageZero’s stock price should be in the range of $0.67 to $14.14; (3) The Discounted Cash Flow (DCF) Method: We estimate that StageZero’s stock price should be $3.18 in one year.